Streetbeat News

Regulatory

IDYA

PFE

Ideaya Biosciences' stock fell 5.3% despite promising interim Phase 2 data for its eye cancer drug, darovasertib. The data showed significant tumor shrinkage and eye preservation rates. Ideaya plans a Phase 3 trial with FDA guidance. The drug is also being tested in collaboration with Pfizer.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 2:07 pm

AEIS

Advanced Energy (NASDAQ:AEIS) has launched the NCF150 series, the world's first off-the-shelf convection cooled CF-rated standard power supplies. These products meet stringent medical equipment safety standards without requiring custom designs, making them suitable for medical devices that may come in direct contact with the heart.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 2:04 pm

UNIUSD

Uniswap CEO Hayden Adams expressed optimism about U.S. Vice President Kamala Harris' supportive comments on digital assets, despite criticism from the crypto community. Adams sees political acknowledgment as progress, though concerns about regulatory threats and Uniswap's governance persist.

Portfolio Pulse from Murtuza Merchant

September 23, 2024 | 1:50 pm

INTC

QCOM

Qualcomm's potential acquisition of Intel could face antitrust challenges, as it would create a major player in the chip industry. The deal could help Qualcomm diversify but may also burden it with Intel's struggling semiconductor unit. Intel's stock rose on the news, while Qualcomm's fell.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 1:49 pm

CAPR

Capricor Therapeutics will host an investor webcast on September 24, 2024, to provide updates on its Duchenne muscular dystrophy program, including recent regulatory discussions with the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:31 pm

F

GM

LI

NIO

XPEV

The U.S. Commerce Department has proposed a ban on Chinese-made vehicles with key communications and automated driving systems due to national security concerns. This could significantly impact Chinese automakers like BYD, Nio, and Xpeng, as well as American and international automakers sourcing components from China. The proposal is part of a broader U.S. strategy to limit China's economic influence. Stocks of affected companies showed mixed reactions, with GM falling over 3% and Ford rising 1.3%.

Portfolio Pulse from Piero Cingari

September 23, 2024 | 1:26 pm

IDYA

Ideaya Biosciences shares rose following positive interim Phase 2 trial data for Darovasertib in Neoadjuvant Uveal Melanoma and a successful FDA type C meeting on trial design for regulatory approval.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:16 pm

MSFT

TSM

UAE President Sheikh Mohamed bin Zayed al-Nahyan is visiting the US to discuss AI cooperation with President Joe Biden. The UAE aims to secure US support for its AI ambitions, reduce fossil fuel dependence, and establish a framework for AI collaboration. The UAE has partnered with Nvidia and announced a $30 billion AI fund with BlackRock, Global Infrastructure Partners, and Microsoft. Additionally, TSM and Samsung are considering building chip megafactories in the UAE.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 12:58 pm

OTRK

The trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. This update may involve OTRK, suggesting potential news or developments related to the company.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:55 pm

VTGN

Vistagen has initiated the PALISADE-4 Phase 3 study for Fasedienol, aimed at treating social anxiety disorder. This marks a significant step in the development of their treatment pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:32 pm